Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interchangeability of Hulio and Humira in Moderate to Severe Chronic Plaque Psoriasis
2021-006015-29Phase 3Completed
- Sponsor
- Viatris
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of adalimumab in psoriasis (2 arms), sponsored by Viatris. Primary endpoint: Primary pharmacokinetic endpoints. Started Jun 2022; status: completed.
02
Drugs
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2021-006015-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006015-29.